Growth & profitability
- Revenue has grown 270.9% per year over the past 3 years.
- Operating margin has expanded, at -3954.3% in the latest year.
Financial health
- Operating income covered interest expense -174.2× in the latest year.
MGRX Financials MANGOCEUTICALS, INC.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $456021 | -$21M | 54.9% | -3954.3% | — | — | $1M |
| 2024 | $615873 | -$9M | 61.7% | -1294.4% | — | — | $58653 |
| 2023 | $731493 | -$9M | 59.0% | -1260.3% | -$7M | — | $739006 |
| 2022 | $8939 | -$2M | 54.3% | -22279.7% | -$1M | — | $682860 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $67864 | -$3M | 42.7% | -4606.8% | — | — | $174562 |
| Dec '25 | $94360 | -$3M | 50.3% | -389.7% | — | — | $1M |
| Sep '25 | $84246 | -$8M | 60.4% | -8953.5% | — | — | $481281 |
| Jun '25 | $168109 | -$5M | 53.5% | -3134.0% | — | — | $101019 |
| Mar '25 | $109306 | -$5M | 56.8% | -4186.8% | — | — | $76496 |
| Dec '24 | $105247 | -$2M | 76.1% | -1594.0% | — | — | $58653 |
| Sep '24 | $133368 | -$2M | 62.0% | -1318.2% | — | — | $73912 |
| Jun '24 | $163163 | -$2M | 42.8% | -1329.1% | — | — | $490243 |
| Mar '24 | $214095 | -$2M | 68.8% | -1105.9% | — | — | $15305 |
| Dec '23 | $244374 | -$3M | 58.3% | -1050.9% | -$2M | — | $739006 |
| Sep '23 | $245160 | -$2M | 59.0% | -734.0% | -$2M | — | $1M |
| Jun '23 | $141237 | -$2M | 61.7% | -1623.0% | -$2M | — | $0 |
| Mar '23 | $100722 | -$3M | 56.8% | -2540.8% | -$2M | — | $0 |
| Dec '22 | — | -$673655 | — | — | -$690131 | — | $682860 |
| Sep '22 | — | -$994915 | — | — | — | — | — |
| Jun '22 | — | -$310185 | — | — | — | — | — |
| Mar '22 | — | -$19599 | — | — | — | — | — |
Valuation over time
How the market has priced MGRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 2285.4× (Mar '23) to 13.9× (Jun '26).
P/S
Frequently asked questions
Is MGRX growing its revenue and profit?
Over the past 3 years, MANGOCEUTICALS, INC.'s revenue has grown 270.9% per year. These are computed facts, not advice.
How much debt does MGRX have?
As of FY2025, MANGOCEUTICALS, INC. reported — of total debt against $1M of cash; operating income covered interest expense -174.2×.
What is MGRX's profit margin?
In FY2025, gross margin was 54.9%, operating margin -3954.3%, and net margin -4526.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.